Closing the HPV Testing Gap Act
Sponsored By: Representative McIver, LaMonica [D-NJ-10]
Introduced
Summary
Standardized, noninvasive HPV testing for men. This bill would require the National Institutes of Health to study how to develop such a test and to coordinate research, pilots, and regulatory pathways across federal agencies.
Show full summary
- Men and families — directs NIH to evaluate methods for noninvasive HPV testing across oral, pharyngeal, anal, penile sites, and urine to identify feasible screening approaches.
- Researchers and agencies — creates an NIH-led interagency working group with the Centers for Disease Control and Prevention, the Food and Drug Administration, the Health Resources and Services Administration, and the National Academy of Medicine to align science, regulation, and community implementation.
- High-risk and underserved communities — requires assessment of pilot and implementation feasibility in diverse populations to inform equitable access.
- Congress and regulators — requires a final report to Congress within 30 months with recommendations for test development, pilot designs, and interagency strategies to support regulatory approval and community screening.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Study to expand HPV testing for men
This bill would require the NIH Director to run a study to develop a standardized, noninvasive HPV test for men. The study would be completed not later than 24 months after enactment and NIH would report to Congress within 30 months. NIH would coordinate with CDC, FDA, HRSA, and the National Academy of Medicine and set up an interagency working group. The study would review current research, evaluate testing methods (oral, pharyngeal, anal, penile, and urine), assess pilot feasibility in high-risk and underserved groups, and recommend steps to facilitate regulatory approval and equitable access. Funding would come from NIH funds made available for fiscal years 2026 through 2030.
Sponsors & CoSponsors
Sponsor
McIver, LaMonica [D-NJ-10]
NJ • D
Cosponsors
Rep. Carter, Troy A. [D-LA-2]
LA • D
Sponsored 5/20/2026
Rep. Menendez, Robert [D-NJ-8]
NJ • D
Sponsored 5/20/2026
Rep. Veasey, Marc A. [D-TX-33]
TX • D
Sponsored 5/20/2026
Rep. Williams, Nikema [D-GA-5]
GA • D
Sponsored 5/21/2026
Rep. Figures, Shomari [D-AL-2]
AL • D
Sponsored 5/21/2026
Rep. Watson Coleman, Bonnie [D-NJ-12]
NJ • D
Sponsored 5/21/2026
Del. Norton, Eleanor Holmes [D-DC-At Large]
DC • D
Sponsored 5/21/2026
Rep. Beatty, Joyce [D-OH-3]
OH • D
Sponsored 5/21/2026
Rep. Velázquez, Nydia M. [D-NY-7]
NY • D
Sponsored 5/21/2026
Rep. Johnson, Henry C. "Hank," Jr. [D-GA-4]
GA • D
Sponsored 5/21/2026
Rep. Simon, Lateefah [D-CA-12]
CA • D
Sponsored 6/2/2026
Rep. Kennedy, Timothy M. [D-NY-26]
NY • D
Sponsored 6/2/2026
Rep. Bynum, Janelle S. [D-OR-5]
OR • D
Sponsored 6/2/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov